Key Takeaways
- • Canyon Partners arranged and anchored NZ$300 million in financing to support Advent International's acquisition of NZCR Group, a physician-led clinical research organization operating across Australia and New Zealand with over 30 years of operational history.
- • NZCR operates integrated Phase I through Phase IV clinical trial capabilities through four branded entities (NZCR, CMAX, Optimal, and Fusion) and maintains established relationships with biotechnology and pharmaceutical sponsors across international markets.
- • The transaction extends the relationship between Canyon and Advent while signaling increased activity by global private credit firms in Australia-New Zealand sponsor-backed transactions outside traditional U.S. and European markets.
- • Advent plans to leverage NZCR's management team and existing shareholders to expand clinical trial capabilities, strengthen sponsor relationships, and increase international reach as the ANZ region attracts a growing share of global clinical trial activity.
- • The deal exemplifies the convergence of private credit and private equity financing structures in cross-border healthcare transactions, with Canyon (managing $30 billion in assets) serving as both arranger and anchor lender.
Summary
Canyon Partners has completed the arrangement and anchor lending of NZ$300 million to finance Advent International's acquisition of NZCR Group, marking a significant transaction in the clinical research services sector and demonstrating the expanding role of private credit in sponsor-backed deals outside core markets. Canyon, a global alternative investment manager with $30 billion in assets under management, structured the financing to support the private equity firm's entry into the Australia and New Zealand clinical research market through the majority acquisition of NZCR.
NZCR Group is a physician-led clinical research organization headquartered in Auckland that operates an integrated platform offering Phase I through Phase IV clinical trial capabilities. The company operates through four distinct brands—NZCR, CMAX, Optimal, and Fusion—and brings more than three decades of clinical research experience to the transaction. The organization maintains established relationships with biotechnology and pharmaceutical sponsors operating in international markets, with particular expertise in early- and later-phase clinical studies.
Advent's acquisition strategy centers on expanding NZCR's capabilities across the full clinical trial spectrum while maintaining engagement with the company's management team and existing clinician shareholders. The private equity firm intends to strengthen sponsor relationships and increase NZCR's international reach, capitalizing on what Canyon Managing Director Maximilian Lichtenheld characterized as "meaningful growth momentum" in the region and the ANZ market's increasing share of global clinical trial activity.
The transaction reinforces the deepening relationship between Canyon and Advent while reflecting broader trends in global private credit deployment. As institutional alternative investment managers seek expanded roles in non-traditional geographies, financing sponsor-backed transactions in Australia and New Zealand has become an increasingly strategic focus. This deal demonstrates how private credit structures are being deployed alongside traditional private equity financing in cross-border healthcare transactions, a sector combining defensive characteristics with compelling growth tailwinds.
NZCR Group is a physician-led clinical research organization headquartered in Auckland that operates an integrated platform offering Phase I through Phase IV clinical trial capabilities. The company operates through four distinct brands—NZCR, CMAX, Optimal, and Fusion—and brings more than three decades of clinical research experience to the transaction. The organization maintains established relationships with biotechnology and pharmaceutical sponsors operating in international markets, with particular expertise in early- and later-phase clinical studies.
Advent's acquisition strategy centers on expanding NZCR's capabilities across the full clinical trial spectrum while maintaining engagement with the company's management team and existing clinician shareholders. The private equity firm intends to strengthen sponsor relationships and increase NZCR's international reach, capitalizing on what Canyon Managing Director Maximilian Lichtenheld characterized as "meaningful growth momentum" in the region and the ANZ market's increasing share of global clinical trial activity.
The transaction reinforces the deepening relationship between Canyon and Advent while reflecting broader trends in global private credit deployment. As institutional alternative investment managers seek expanded roles in non-traditional geographies, financing sponsor-backed transactions in Australia and New Zealand has become an increasingly strategic focus. This deal demonstrates how private credit structures are being deployed alongside traditional private equity financing in cross-border healthcare transactions, a sector combining defensive characteristics with compelling growth tailwinds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.